Chronic Cough
Read Time: 8 mins

Future Directions in Chronic Cough

Copy Link
Published Online: Jun 30th 2023 touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):28–32 DOI:
Authors: James Wingfield Digby, Jenny King, Jaclyn Smith, Paul Marsden
Quick Links:
Article Information


Refractory/unexplained chronic cough (RUCC) is a highly prevalent debilitating condition. The characteristics of RUCC suggest neuronal excitability. The biological mechanisms leading to this in humans are uncertain but are thought to involve changes in both the peripheral and central nervous system. Efficacy of P2X purinoceptor 3 (P2X3) antagonists suggests a role for extracellular adenosine triphosphate (ATP) in RUCC. In guinea pigs, ATP release occurs in response to hypotonic saline, through a transient receptor potential cation channel subfamily V member 4 (TRPV4)ATPP2X3 axis.


In this review we discuss data from two European Respiratory Society 2022 abstracts in RUCC, as well as current insights and future directions in chronic cough.


We show that hypotonic saline cough challenge, measured by maximum evoked cough response, effectively discriminates RUCC from healthy volunteers. We show that low-dose morphine is efficacious in up to 75% of patients with RUCC and that side effects, experienced in around 38% of cases, can usually be managed.

Further areas

We discuss treatable traits in chronic cough, existing pharmacological management options and future antitussives.


Adenosine triphosphate, antitussive agents, chronic cough, cough, hypotonic saline cough challenge, P2X3 purinoceptor antagonists, peripheral and central sensitization, RUCC, treatable traits


Chronic cough, defined as a cough lasting over 8 weeks, has an estimated global prevalence of 10% and has significant detrimental physical, social and psychological consequences on individuals.1,2 Chronic cough is a complex heterogeneous disease, in which many causative factors need to be explored (Figure 1).3 The three most reported associations are rhinosinusitis, gastro-oesophageal reflux disease and asthma.4 However, up to 59% of patients seen in specialist cough clinics have persistent symptoms despite treatment of these three triggers.5 Typically, these patients share similar characteristics, including an irritation or tickle in their throat and intense coughing to low-level stimuli (hypertussia), such as exposure to cold temperature, dry atmospheres and talking.6,7 This symptom set, alongside hypersensitivity and hyperresponsiveness to inhaled tussive agents compared with healthy volunteers, strongly suggest a neuropathic basis for the disorder.8 In this review we discuss the physiology of the chronic reflex and recent research in refractory/unexplained chronic cough (RUCC).

Overview of the cough neuroanatomy

In humans, cough is under a combination of reflex and volitional control.9 Two categories of nerve fibres are primarily responsible for mediating cough: vagus A-fibres and C-fibres (Table 1).10 A-fibres are myelinated, thus have a fast speed of conduction (<2 m/s) and respond primarily to mechanical forces and acid. C-fibres, on the other hand, are unmyelinated, transmitting impulses at slower conduction speeds of 5 m/s but responding to a wider array of substances, including capsaicin, bradykinin and prostaglandin.11 Their cell bodies are in separate ganglia, nodose (A-fibres) and jugular (C-fibres), and terminate in two slightly separate areas within the medulla oblongata of the brainstem.12 P2X purinoceptor 3 (P2X3) receptors are adenosine triphosphate (ATP)-activated ion channels located widely in the peripheral nervous system, including on both A and C-fibres innervating the airways.13 Alongside other afferent nerve receptors, including transient receptor potential cation channel subfamily V member 1 (TRPV1) and TRPA1, they are thought to play a prominent role in cough neurophysiology.14 Supporting this concept, P2X3 antagonism has been shown to dramatically reduce cough frequency in patients with RUCC.15 In addition, cough control is influenced by the central nervous system, which can have both facilitatory and inhibitory effects on the cough reflex.9

Adenosine triphosphate and hypotonic saline challenge

Landmark trials demonstrating the efficacy of blocking the purinergic receptor, P2X3 (or heterotrimeric P2X2/3 receptor), in RUCC have sparked heightened interest in the mechanistic role of extracellular ATP in chronic cough.15,16 The mechanism in which ATP is released, or whether vagus afferent nerves are simply sensitized to ATP, is not known. Bonvini et al. have previously demonstrated that ATP release in guinea pigs occurs through an indirect mechanism involving TRPV4.13 In this model, hypotonicity (-80 Osm/L) activates TRPV4 receptors, leading to ATP release via the ion channel pannexin 1, and subsequent depolarization of A-fibres (Figure 2).13

Whether a similar mechanism occurs in humans is unknown, but in our recent European Respiratory Society (ERS) abstract we demonstrate that hypotonic saline effectively discriminates RUCC from healthy volunteers.17 In this study, a typical cohort of participants with RUCC (n=38) were recruited and compared with healthy volunteers (n=38). Descending concentrations of hypotonic saline (300, 250, 200, 150, 100 mOsm/kg) were given in four single breath activations via a DeVilbiss 3000 ultrasonic nebulizer (DeVilbiss Healthcare Ltd., West Midlands, UK). The maximum number of coughs evoked at any given dose (Emax) was recorded for each participant.

Median (interquartile range) Emax was significantly higher in participants with RUCC (11.50 [4.75–24.25]) than in healthy volunteers (0.00 [0.00–2.00]; p<0.01). The observed cough frequency was higher across all concentrations in the RUCC group, but peaked at 150 mOsm/kg. Interestingly, in the RUCC group, the median (interquartile range) Emax was significantly higher in females (22.00 [6.00–30.00]) compared with males (6.00 [3.00–13.00]; p=0.02).

Hypotonic saline is a novel cough challenge that effectively discriminates RUCC from healthy volunteers. Compared with other cough challenge agents, such as capsaicin and citric acid, there is less overlap in evoked cough between health and disease.18 The observed differences are consistent with experiments in animal models, and suggest that the TRPV4–ATP–P2X3 axis may play a role in the pathophysiology of RUCC. Unfortunately, a small phase IIa study assessing the efficacy of a TRPV4 antagonist in RUCC showed no significant effect on cough frequency, but adequate dosing and effective target engagement were not demonstrated.19

Evidence for central mechanismsin refractory/unexplained chronic cough

Our group have recently shown that compared with healthy volunteers, patients with RUCC have increased cough responses to a range of tussive challenge agents that stimulate receptors on both A-fibres and C-fibres, including citric acid and capsaicin.18 This indiscriminate hypersensitivity suggests that, alongside factors stimulating peripheral nerves, central sensitization is implicated in the pathophysiology of RUCC. Central control of cough is also evident by varying behavioural responses to tussive stimuli (Figure 3),20 and further supported by the efficacy of centrally acting medications, such as opioids, in RUCC.21 Likewise, speech and language therapy, which is effective in RUCC, targets top-down control of cough, particularly the patient response to an urge to cough.22 Further evidence of central control of cough is seen with functional magnetic resonance imaging (fMRI). During simultaneous fMRI and capsaicin challenge, urge to cough was matched with higher blood oxygen level-dependent (BOLD) signal in midbrain processing regions, such as the periaqueductal grey and dorsal raphe nucleus, in RUCC compared with healthy volunteers.23 This heightened neural activity suggests that interoceptive pathways may be upregulated in RUCC, leading to increased responses to nociceptive stimuli. Interestingly, in the same study, patients with RUCC also had reduced BOLD responses in frontal network areas associated with suppression of motor reflexes. This suggests that both upregulated central nervous system processing and reduced cortical cough control may be implicated in the physiology of RUCC.

Pharmacological management of refractory/unexplained chronic cough

Despite a high burden of symptoms, treatment options are limited in RUCC. Low-dose morphine has been shown to lower cough frequency and improve patient-reported outcomes in RUCC,21,24 but there are concerns regarding tolerability of this medication, particularly considering the recent epidemic of opiate use in the United States.25 European guidelines do, however, recommend considering a trial of low-dose morphine (5–10 mg twice daily) in patients with RUCC under the care of a specialist cough clinic.26 Alternative options include gabapentin, pregabalin or amitriptyline, but the evidence for the efficacy of these medications is weaker.27–29

In our recent ERS abstract, we highlight the real-world effectiveness and tolerability of low-dose opiates in RUCC (n=100).30 In this retrospective review, the side effects and efficacy, as measured by a verbal (0–10) cough score, were recorded. The most used formulation and dose was 5 mg slow-release morphine sulphate tablets (MST) twice daily. We found that 75% of patients experienced some benefit in cough symptoms. Side effects did occur (38%), but could be managed with adjuncts or changes in formulation in the majority of patients (23 out of 38). Novel antitussives are needed to optimize care of patients with RUCC, but this study highlights acceptable tolerability of MST in this cohort, who were managed and closely observed under a specialist cough clinic.

Targeting specific traits in chronic cough

International guidelines have highlighted the importance of identifying treatable traits in chronic cough,26 and previously set out investigation and treatment algorithms for common associations such as asthma, acid reflux and nasal disease (summarized in Table 2).26,31,32 There is less consensus on evaluation of treatment responses. There is a relationship between patient-reported outcomes (Leicester Cough Questionnaire and cough severity visual analogue scale) and 24-hour cough frequency, but the correlation is only weak to moderate in strength (p=0.30–0.58).33 These measures also do not help characterize specific traits in RUCC. Features of neuronal excitability, such as a background urge to cough and numerous cough triggers are common in RUCC, but not reported in all patients.7 The response of these cough characteristics to treatment has not been well described. Recently, the triggers and sensations provoking cough in different respiratory conditions were compared using a novel 49-item questionnaire.34 Interestingly, compared with other conditions, such as asthma, interstitial lung disease and bronchiectasis, patients with RUCC reported a greater number and severity of triggers and sensations associated with their cough. How these characteristics change over time and with treatment is an on-going area of intrigue.

Another area of interest is patients with RUCC who display atypical characteristics, such as excessive sputum production (>1 tablespoon sputum daily) or an urge to cough associated with sensations located in the chest. These patients have historically been poorly characterized in the literature, despite making up to 21% of patients seen in specialist cough clinic.35 In this cohort, alongside cough hypersensitivity, additional factors should be considered and investigated such as: airway collapsibility (excessive dynamic airway collapse and tracheobronchomalacia; Figure 4), neutrophilic inflammation and eosinophilic bronchitis.36 These patients share similarities with non-cystic fibrosis bronchiectasis, where chest physiotherapy and daily nebulized hypertonic saline have been shown to improve patient-reported outcomes and lung function.37,38 Azithromycin, which can also be trialled in this cohort, has not been found to be broadly helpful in RUCC,39 but may offer benefit in subgroups with sputum production.40

Future treatments

Gefapixant is an investigational, orally administered drug that is being developed for the treatment of RUCC. The antitussive effects of gefapixant are thought to occur primarily through P2X3 antagonism, with taste side effects related to co-existing blockade of P2X2/3 receptors on the nerves innervating the tongue.41,42 In the COUGH-1 and COUGH-2 phase III studies, there was a high incidence of taste side effects, with 20% unable to continue gefapixant 45 mg twice daily due to adverse effects.43 It is therefore of interest that a recent phase IIa randomized placebo-controlled trial of the highly selective P2X3 antagonist, sivopixant, met the endpoint of demonstrating a significant reduction in placebo-adjusted average daytime cough frequency (-31%; p=0.0546), with patients reporting a lower incidence of taste side effects (12.9%).44 Having therapeutic options for targeting peripheral P2X3 receptors (selective and non-selective antagonists) and thereby reducing cough frequency will improve patient care, but centrally acting medications are also likely to remain important. Our review suggests that low-dose MST is well tolerated in RUCC, but there remains a low risk of addiction and side effects. Nalbuphine is an opiate that may negate this risk, as it is a dual-acting κ-opioid receptor agonist and µ-opioid receptor antagonist. It is therefore of interest that this medication is highly effective in cough associated with idiopathic pulmonary fibrosis, with a recent study demonstrating a significant reduction in placebo-adjusted hourly cough frequency using this medication (day 22 versus baseline, -51.6%; p<0.0001).45

Several mechanisms are likely to play a part in the presence of RUCC both within and between individuals. As described above, the response to individual antitussive agents is not uniform. The development of tools or biomarkers to predict an individual’s response to antitussive therapy would be an important development to reduce the burden of side effects and risks associated with pharmacological agents.


The mechanisms underpinning chronic cough are complex and multi-factorial, but our knowledge of neuronal hypersensitivity is increasing. The efficacy of P2X3 antagonists and cough reflex hypersensitivity and hyperresponsiveness to hypotonic saline suggest a role for extracellular ATP in this disorder. Future treatment may be multi-faceted, with treatment targeting control of underlying triggers and modulation of central and peripheral mechanisms leading to cough (Figure 5).

Article Information:

Jaclyn Smith has received grants or contracts from Bellus Health Inc., NIHR Manchester Biomedical Research Centre and Wellcome Investigator Award; has received royalties or licenses from Vitalograph Ltd; has received consulting fees from Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, Merck, Nocion, Shionogi and Trevi; has received payment or honoraria from Merck; has a patent issued for cough monitoring and; has received equipment from Vitalograph Ltd. Paul Marsden has been awarded investigator initiated research funding by Merck and has received lecture fees from Olympus. James Wingfield Digby and Jenny King have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


James Wingfield DigbyDepartment of Respiratory, Allergy and ImmunologyUniversity of Manchester, Wythenshawe Hospital Education and Research Centre, Manchester, M239LT, UK;


No funding was received in the publication of this article.


This article is freely accessible at ©Touch Medical Media 2023.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




1. Song W-JChang Y-SFaruqi Set alThe global epidemiology of chronic cough in adults: A systematic review and meta-analysisEur Respir J2015;45:147981DOI10.1183/09031936.00218714

2. Won H-KSong W-JImpact and disease burden of chronic coughAsia Pac Allergy2021;11:e22. DOI: 10.5415/apallergy.2021.11.e22

3. Barraclough KChronic cough in adultsBMJ2009;338:b1218DOI10.1136/bmj.b1218

4. Smith JAWoodcock AChronic coughN Engl J Med2016;375:154451. DOI: 10.1056/NEJMcp1414215

5. Al-Sheklly BSatia IBadri Het alP5 prevalence of refractory chronic cough in a tertiary cough clinic. Thorax. 2018;73:A98DOI10.1136/thorax-2018-212555.163

6. Smith JASatia IBadri HMarsden PMini-review: Hypertussivity and allotussivity in chronic cough endotypes. Neurosci Lett. 2023;792:136934DOI10.1016/j.neulet.2022.136934

7. Hilton EMarsden PThurston Aet alClinical features of the urge-to-cough in patients with chronic cough. Respir Med. 2015;109:7017DOI10.1016/j.rmed.2015.03.011

8. Satia IBadri HAl-Sheklly Bet alTowards understanding and managing chronic coughClin Med (Lond). 2016;16:s927DOI10.7861/clinmedicine.16-6-s92

9. Mazzone SBCole LJAndo Aet alInvestigation of the neural control of cough and cough suppression in humans using functional brain imagingJ Neurosci. 2011;31:294858. DOI: 10.1523/JNEUROSCI.4597-10.2011

10. Canning BJChang ABBolser DCet alAnatomy and neurophysiology of cough: CHEST guideline and expert panel reportChest2014;146:163348DOI10.1378/chest.14-1481

11. Canning BJAfferent nerves regulating the cough reflex: Mechanisms and mediators of cough in disease. Otolaryngol Clin North Am2010;43:1525DOI10.1016/j.otc.2009.11.012

12. Chung KFMcGarvey LSong W-Jet alCough hypersensitivity and chronic coughNat Rev Dis Primers. 2022;8:45. DOI: 10.1038/s41572-022-00370-w

13. Bonvini SJBirrell MAGrace MSet alTransient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphateJ Allergy Clin Immunol. 2016;138:24961. DOI: 10.1016/j.jaci.2015.10.044

14. Zhang MWang SYu Let alThe role of ATP in cough hypersensitivity syndrome: New targets for treatment. J Thorac Dis2020;12:278190DOI10.21037/jtd-20-cough-001

15. Abdulqawi RDockry RHolt Ket alP2X3 receptor antagonist (AF-219) in refractory chronic cough: A randomised, double-blind, placebo-controlled phase 2 studyThe Lancet. 2015;385:1198205. DOI: 10.1016/S0140-6736(14)61255-1

16. McGarvey LPBirring SSMorice AHet alEfficacy and safety of gefapixant, a P2X (3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): Results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399:90923. DOI10.1016/S0140-6736(21)02348-5

17. Wingfield Digby JKing JDockry Ret alHypotonic saline effectively discriminates refractory/unexplained chronic cough from healthy volunteersEur Respir J.. 2022;60:1163. DOI: 10.1183/13993003.congress-2022.1163

18. King JAl-Sheklly BDigby JWet alRefractory chronic cough patients are indiscriminately hyper-responsive to inhaled tussive irritants/agents. B40 assessment and treatment of cough and dyspneaAm J Respir Crit Care Med2022;A2809DOI10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A2809

19. Ludbrook VJHanrott KEKreindler JLet alAdaptive study design to assess effect of TRPV4 inhibition in patients with chronic coughERJ Open Res. 2021;7:00269-2021. DOI: 10.1183/23120541.00269-2021

20. Ando AFarrell MJMazzone SBCough-related neural processing in the brain: A roadmap for cough dysfunction? Neurosci Biobehav Rev2014;47:45768DOI10.1016/j.neubiorev.2014.09.018

21. Al-Sheklly BMitchell JIssa Bet alS35 Randomised control trial quantifying the efficacy of low dose morphine in a responder group of patients with refractory chronic cough. Thorax. 2017;72:A245. DOI: 10.1136/thoraxjnl-2017-210983.41

22. Ryan NMVertigan AEBone SGibson PGCough reflex sensitivity improves with speech language pathology management of refractory chronic coughCough2010;6:5DOI10.1186/1745-9974-6-5.

23. Ando ASmallwood DMcMahon Met alNeural correlates of cough hypersensitivity in humans: Evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016;71:3239. DOI: 10.1136/thoraxjnl-2015-207425

24. Morice AHMenon MSMulrennan SAet alOpiate therapy in chronic coughAm J Respir Crit Care Med. 2007;175:3125DOI10.1164/rccm.200607-892OC

25. The LancetA time of crisis for the opioid epidemic in the USA. Lancet. 2021;398:277. DOI: 10.1016/S0140-6736(21)01653-6

26. Morice AHMillqvist EBieksiene Ket alERS guidelines on the diagnosis and treatment of chronic cough in adults and childrenEur Respir J2020;55:1901136DOI10.1183/13993003.01136-2019

27. Ryan NMBirring SSGibson PGGabapentin for refractory chronic cough: A randomised, double-blind, placebo-controlled trialThe Lancet2012;380:15839DOI10.1016/S0140-6736(12)60776-4

28. Vertigan AEKapela SLRyan NMet alPregabalin and speech pathology combination therapy for refractory chronic coughChest2016;149:63948DOI10.1378/chest.15-1271

29. Ryan MACohen SMLong-Term follow-up of amitriptyline treatment for idiopathic coughThe Laryngoscope. 2016;126:275863DOI10.1002/lary.25978

30. King JWingfield-Digby JHennessey Set alReal world effectiveness and tolerability of low-dose opiates for refractory/unexplained chronic cough (RCC/UCC) in a tertiary clinicEur Respir J. 2022;60:1159. DOI10.1183/13993003.congress-2022.1159

31. Smith JABirring SSDicpinigaitis PVet alImprovements in objective and subjective measures of chronic cough with gefapixant: A pooled phase 3 efficacy analysis of predefined subgroups. Lung. 2022;200:4239. DOI: 10.1007/s00408-022-00553-y

32. Morice AHMcGarvey LPavord IBritish Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adultsThorax2006;61(Suppl. 1):i124. DOI: 10.1136/thx.2006.065144.

33. Schelfhout JNguyen AMBirring SSet alValidation and meaningful change thresholds for an objective cough frequency measurement in chronic coughLung. 2022;200:71724. DOI: 10.1007/s00408-022-00587-2

34. Galgani SBoone LWingfield-Digby Jet alS18 Describing the triggers and sensations associated with coughing across different disease groupsThorax2022;77:A15DOI10.1136/thorax-2022-BTSabstracts.24

35. King JWingfield Digby JHennessey Set alProductive cough, a forgotten phenotype of refractory chronic cough. Eur Respir J2021;58:PA1941DOI10.1183/13993003.congress-2021.PA1941

36. Wingfield Digby JKing JSmith Jet alBronchoscopy and laryngoscopy findings in refractory chronic cough (RCC)Eur Respir J2021;58:PA1936DOI10.1183/13993003.congress-2021.PA1936

37. Nicolson CHHStirling RGBorg BMet alThe long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasisRespir Med2012;106:6617DOI10.1016/j.rmed.2011.12.021

38. Murray MPPentland JLHill ATA randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasisEur Respir J2009;34:108692DOI10.1183/09031936.00055509

39. Hodgson DAnderson JReynolds Cet alThe effects of azithromycin in treatment-resistant cough: A randomized, double-blind, placebo-controlled trialChest. 2016;149:105260. DOI: 10.1016/j.chest.2015.12.036

40. Martin MJLee HClayton Cet alIdiopathic chronic productive cough and response to open-label macrolide therapy: An observational studyRespirology2019;24:55865DOI10.1111/resp.13483

41. High BJetté MELi Met alVariability in P2X receptor composition in human taste nerves: Implications for treatment of chronic coughERJ Open Res2023;9:00007-2023. DOI: 10.1183/23120541.00007-2023.

42. Thomas DGibson PGGefapixant for chronic coughLancet. 2022;399:8867. DOI: 10.1016/S0140-6736(21)02438-7.

43. McGarvey LPBirring SSMorice AHet alEfficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): Results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsThe Lancet. 2022;399:90923. DOI: 10.1016/S0140-6736(21)02348-5

44. Niimi ASaito JKamei Tet alRandomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic coughEur Respir J2022;59:2100725DOI10.1183/13993003.00725-2021

45. Molyneaux PLForbes WBortey Eet alS15 Efficacy of oral nalbuphine extended release for the treatment of chronic cough in idiopathic pulmonary fibrosis: Analysis of a phase 2 studyThorax. 2022;77:A134. DOI10.1136/thorax-2022-BTSabstracts.21

Further Resources

Share this Article
Related Content In Chronic Cough
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72